Member Info for itsallamess

Imagine being one of those end of line patients, exhusted all other options, probably chemo and radiated to half death, and then comes bex and 14.9 months later, you are still alive!

"Median overall survival based on patients from Part I and II (n=138) was 14.9 months for patients who benefited from treatment with bexmarilimab compared to 4.4 months for those who did not, representing a 3.4-fold increase"

4 trades value at £9,994

That looks like 10 grand less 6 quid commission

https://www.faron.com/faron/meet-team

Q&A with Dr. Jonathan Knowles, Scientific Advisory Board Chair
May 2022

Google showing 1.94

Things are looking up.

Said it before as the saying goes, 'the darkest hour is just before dawn"

Brig on the sunshine Markku

https://twitter.com/MedicityL/status/1570064253561741314?t=c0miBRZmDX-vStMdG20kNQ&s=19

Google showing 1.80!

Perhaps the ship has finally turned

Looking forward to this, hopefully new data that will raise the Share price

"We've significantly advanced our bexmarilimab development program in 2022 and on this webcast, will provide updates on current trials and important milestones we expect to achieve over the coming months."

We are not on anybodies radar ATM.

Maybe after this conference thing the faron name may become known.

"Traumakine holds the promise to be an important 'golden hour' therapeutic within combat scenarios where there remains a serious unmet need."

The darkest hour is just before dawn.. hang in there guys.. personally I have been waiting a long time, waiting longer I no issue for me.

I'll see if we drop more but I may well buy more

It would be interesting to have the perspective of him speaking in his native language. If we understood I'm sure we would get a better picture of his excitement

https://faron.videosync.fi/2022-halfyear-results

https://twitter.com/InFLAMES_Health/status/1563100958871388160?t=ttqYQqnFPhmMJOWRa6MQ2Q&s=19

https://www.proactiveinvestors.co.uk/companies/news/991000/faron-pharma-to-focus-on-accelerating-bexmarilimab-s-clinical-development-in-second-half-991000.html

Any thoughts on Marcus reaction when mentioning the results of bex on leukemia. He seemed very happy with the results to date of how bex worked with this.

Was he playing up to the recent investors from the leukemia foundation?

Been here since 2018 and have no intention of selling but like sax, don't want.to see 50 million dilution.

I think they know that bex will have benefits for a wide range of cancers but my feeli g is they need to concentrate on a couple of big winners to generate income rather than try to find all the winners now and never get anything to market...

Thinking about what they said about future finances.

They are talking to possible partners but they are taking their time to see if its a good deal for the shareholder or if they can fo it alone.

Deciding factor is funding.
They need 50 million for next stage then 100 million for th e stage after that.

3 things come to mind
1. Sell.out and its payday for everyone
2. Partner up and the final payday may not be so big. (It may just be a exit plan for us small holders.
3. Raise the 150 million alone via placings and loans and grants and us listing..
(The issue I have with this is that we will be diluted alot)

On the other hand, markku and team have bought alot higher than we arr now but was that with free money granted to them or their own cash, which is still from wages paid via money from funding?

That's it...

Didn't catch some things and was typing as I went so some comments may be illegible...

But the presentation will be posted on the website soon

Traumakine

Tests are still on going with the US medical side for battlefield wounds.

Waiting for data to design a trial

Seeking us listing?
Expanding clinical group over there, interested in setting up regulatory work.. for FDS

Haven't said they will list on nasdaq but they have high interest there but being cautious as the US markets have been down.

But they are exploring this option

Bexmab timeliness

Planning to expand into US